Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 11/2020

01-11-2020 | Systemic Sclerosis | Original Article

Performance evaluation of a commercial line blot assay system for detection of myositis- and systemic sclerosis-related autoantibodies

Authors: Yasuhito Hamaguchi, Masataka Kuwana, Kazuhiko Takehara

Published in: Clinical Rheumatology | Issue 11/2020

Login to get access

Abstract

Introduction/Objectives

A line blot (LB) assay is a multi-analyte platform capable of simultaneously detecting multiple anti-nuclear antibody specificities. Here, we evaluated the performance of a commercial LB assay developed for the identification of myositis- or systemic sclerosis (SSc)-related autoantibodies (autoAbs).

Method

We screened 300 serum samples from patients with various connective tissue diseases using an LB assay and compared the results of myositis- or SSc-related autoAbs with those identified by RNA and protein immunoprecipitation (IP) assays or indirect immunofluorescence (IIF).

Results

The IP assays revealed anti-Jo-1 Abs in 14 patients, anti-EJ Abs in 12, anti-PL-7 Abs in 8, anti-PL-12 Abs in 4, anti-Mi-2 Abs in 6, anti-SRP Abs in 8, anti-topoisomerase I Abs in 54, anti-RNA polymerase III Abs in 24, anti-U3 RNP Abs in 9, anti-Th/To Abs in 9, anti-Ku Abs in 14 and anti-hUBF Abs in 4, whereas IIF identified anti-centromere in 35. Good agreement between the IP assays and the LB assay was found only for anti-Jo-1 and anti-centromere antibodies. When a cut-off was adjusted to reconcile with the results of IP assays, the detection performance of LB assay was improved for anti-EJ, anti-PL-7, anti-PL-12, anti-SRP, anti-topoisomerase I and anti-RNA polymerase III Abs. However, the results of anti-Mi-2, anti-U3 RNP, anti-Th/To, anti-hUBF and anti-Ku Abs remained discordant between the LB assay and IP assays at all cut-off levels.

Conclusions

Detection of myositis- or SSc-related autoAbs using a commercial LB assay requires great caution since it can yield analytically false-positive or false-negative results.
Key Points
• A line blot (LB) assay is a multi-analyte platform capable of simultaneously detecting multiple antibodies with anti-nuclear specificities.
• Detection of myositis- or systemic sclerosis-related autoantibodies using a commercial LB assay requires great caution since it can yield analytically false-positive or false-negative results.
Literature
1.
Targoff IN (2002) Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheumatic diseases clinics of North America 28(4):859–890PubMed
2.
McHugh NJ, Tansley SL (2018) Autoantibodies in myositis. Nat Rev Rheumatol 14(5):290–302PubMed
3.
Steen VD (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35(1):35–42PubMed
4.
Hamaguchi Y (2010) Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol 37(1):42–53PubMed
5.
Hamaguchi Y, Takehara K (2018) Anti-nuclear autoantibodies in systemic sclerosis: news and perspectives. J Scleroderma Relat Dis 3(3):201–213
6.
Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N (2016) Recent advances in dermatomyositis-specific autoantibodies. Curr Opin Rheumatol 28(6):636–644PubMed
7.
8.
Cruellas MG, Viana Vdos S, Levy-Neto M, Souza FH, Shinjo SK (2013) Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics (Sao Paulo) 68(7):909–914
9.
Song JS, Hwang J, Cha HS, Jeong BH, Suh GY, Chung MP, Kang ES (2015) Significance of myositis autoantibody in patients with idiopathic interstitial lung disease. Yonsei Med J 56(3):676–683PubMedPubMedCentral
10.
Patterson KA, Roberts-Thomson PJ, Lester S, Tan JA, Hakendorf P, Rischmueller M, Zochling J, Sahhar J, Nash P, Roddy J, Hill C, Nikpour M, Stevens W, Proudman SM, Walker JG (2015) Interpretation of an extended autoantibody profile in a well-characterized australian systemic sclerosis (Scleroderma) cohort using principal components analysis. Arthritis Rheumatol 67(12):3234–3244PubMed
11.
Sujau I, Ng CT, Sthaneshwar P, Sockalingam S, Cheah TE, Yahya F, Jasmin R (2015) Clinical and autoantibody profile in systemic sclerosis: baseline characteristics from a West Malaysian cohort. Int J Rheum Dis 18(4):459–465PubMed
12.
Mejia M, Herrera-Bringas D, Perez-Roman DI, Rivero H, Mateos-Toledo H, Castorena-García P, Figueroa JE, Rojas-Serrano J (2017) Interstitial lung disease and myositis-specific and associated autoantibodies: Clinical manifestations, survival and the performance of the new ATS/ERS criteria for interstitial pneumonia with autoimmune features (IPAF). Respir Med 123:79–86PubMed
13.
Yang H, Peng Q, Yin L, Li S, Shi J, Zhang Y, Lu X, Shu X, Zhang S, Wang G (2017) Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res Ther 19(1):259–267PubMedPubMedCentral
14.
Aouizerate J, De Antonio M, Bader-Meunier B, Barnerias C, Bodemer C, Isapof A, Quartier P, Melki I, Charuel JL, Bassez G, Desguerre I, Gherardi RK, Authier FJ, Gitiaux C (2018) Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis. Rheumatology (Oxford). 57(5):873–879PubMed
15.
Chen F, Li S, Wang T, Shi J, Wang G (2018) Clinical heterogeneity of interstitial lung disease in polymyositis and dermatomyositis patients with or without specific autoantibodies. Am J Med Sci. 355(1):48–53PubMed
16.
Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292(8):403–407PubMed
17.
Anonymous (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23:581–590
18.
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMed
19.
Arnett FC, Edworthy SM, Bloch DA, Mcshane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324PubMed
20.
Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH, European Study Group on Classification Criteria for Sjögren's Syndrome (2002) Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61(6): 554-558
21.
Moroi Y, Peebles C, Fritzler MJ, Steigerwald J, Tan EM (1980) Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci U S A. 77(3):1627–1631PubMedPubMedCentral
22.
Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, Komura K, Nakamura M, Kodera M, Suga N, Higashi A, Ogusu K, Tsutsui K, Furusaki A, Tanabe H, Sasaoka S, Muro Y, Yoshikawa M, Ishiguro N, Ayano M, Muroi E, Fujikawa K, Umeda Y, Kawase M, Mabuchi E, Asano Y, Sodemoto K, Seishima M, Yamada H, Sato S, Takehara K, Fujimoto M (2011) Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 147(4):391–398PubMed
23.
Fujimoto M, Matsushita T, Hamaguchi Y, Asano Y, Ogawa F, Yamaoka T, Fujikawa K, Tsukada T, Sato K, Echigo T, Hasegawa M, Takehara K (2013) Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort. Ann Rheum Dis 72(1):151–153PubMed
24.
Hamaguchi Y, Hasegawa M, Fujimoto M, Matsushita T, Komura K, Kaji K, Kondo M, Nishijima C, Hayakawa I, Ogawa F, Kuwana M, Takehara K, Sato S (2018) The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol 158(3):487–495
25.
Suzuki S, Satoh T, Sato S, Otomo M, Hirayama Y, Sato H, Kawai M, Ishihara T, Suzuki N, Kuwana M (2008) Clinical utility of anti-signal recognition particle antibody in the differential diagnosis of myopathies. Rheumatology (Oxford) 47(10):1539–1542
26.
Hamaguchi Y, Fujimoto M, Matsushita T, Kaji K, Komura K, Hasegawa M, Kodera M, Muroi E, Fujikawa K, Seishima M, Yamada H, Yamada R, Sato S, Takehara K, Kuwana M (2013) Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One 8(4):e60442PubMedPubMedCentral
27.
Satoh T, Ishikawa O, Ihn H, Endo H, Kawaguchi Y, Sasaki T, Goto D, Takahashi K, Takahashi H, Misaki Y, Mimori T, Muro Y, Yazawa N, Sato S, Takehara K, Kuwana M (2009) Rheumatology (Oxford) 48(12):1570–1574
28.
Suzuki S, Hayashi YK, Kuwana M, Tsuburaya R, Suzuki N, Nishino I (2012) Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome. Arch Neurol 69(6):728–732PubMed
29.
Hamaguchi Y, Kodera M, Matsushita T et al (2015) Clinical and immunologic predictors of scleroderma renal crisis in japanese systemic sclerosis patients with anti-rna polymerase III autoantibodies. Arthritis Rheumatol 67(4):1045–1052PubMed
30.
Aggarwal R, Dhillon N, Fertig N, Koontz D, Qi Z, Oddis CV (2017) A negative antinuclear antibody does not indicate autoantibody negativity in myositis: role of anticytoplasmic antibody as a screening test for antisynthetase syndrome. J Rheumatol 44(2):223–229PubMed
31.
Homer KL, Warren J, Karayev D, Khanna PP, Young A, Nagaraja V, Metzger AL, Khanna D (2018) Performance of anti-topoisomerase i antibody testing by multiple-bead, enzyme-linked immunosorbent assay and immunodiffusion in a university setting. J Clin Rheumatol
32.
Cavazzana I, Fredi M, Ceribelli A, Mordenti C, Ferrari F, Carabellese N, Tincani A, Satoh M, Franceschini F (2016) Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera. J Immunol Methods 433:1–5PubMed
33.
Kuwana M (2017) Circulating Anti-Nuclear Antibodies in Systemic Sclerosis: Utility in Diagnosis and Disease Subsetting J Nippon Med Sch 84(2):56–63PubMed
34.
Hamaguchi Y, Kuwana M, Takehara K (2017) Comparison of anti-OJ antibody detection assays between an immunoprecipitation assay and line blot assay. Mod Rheumatol. 27(3):551–552PubMed
35.
Vulsteke JB, Satoh M, Malyavantham K, Bossuyt X, De Langhe E, Mahler M (2019) Anti-OJ autoantibodies: Rare or underdetected? Autoimmun Rev 18(7):658–664PubMed
36.
Espinosa-Ortega F, Holmqvist M, Alexanderson H, Storfors H, Mimori T, Lundberg IE, Rönnelid J (2019) Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies. Ann Rheum Dis 78(6):858–860PubMed
37.
Mahler M, Betteridge Z, Bentow C, Richards M, Seaman A, Chinoy H, McHugh N (2019) Comparison of three immunoassays for the detection of myositis specific antibodies. Front Immunol 10:848PubMedPubMedCentral
38.
Vulsteke JB, De Langhe E, Claeys KG, Dillaerts D, Poesen K, Lenaerts J, Westhovens R, Van Damme P, Blockmans D, De Haes P, Bossuyt X (2019) Detection of myositis-specific antibodies. Ann Rheum Dis 78(1):e7PubMed
39.
Montagnese F, Babacic H, Eichhorn P, Schoser B (2019) Evaluating the diagnostic utility of new line immunoassays for myositis antibodies in clinical practice: a retrospective study. J Neurol 266(6):1358–1366PubMed
40.
Zampeli E, Venetsanopoulou A, Argyropoulou OD, Mavragani CP, Tektonidou MG, Vlachoyiannopoulos PG, Tzioufas AG, Skopouli FN, Moutsopoulos HM (2019) Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies. Clin Rheumatol 38(1):125–132PubMed
41.
Bundell C, Rojana-Udomsart A, Mastaglia F, Hollingsworth P, McLean-Tooke A (2016) Diagnostic performance of a commercial immunoblot assay for myositis antibody testing. Pathology 48(4):363–366PubMed
42.
Chang WS, Schollum J, White DH, Solanki KK (2015) A cross-sectional study of autoantibody profiles in the Waikato systemic sclerosis cohort, New Zealand. Clin Rheumatol 34(11):1921–1927PubMed
43.
Foocharoen C, Watcharenwong P, Netwijitpan S, Mahakkanukrauh A, Suwannaroj S, Nanagara R (2017) Relevance of clinical and autoantibody profiles in systemic sclerosis among Thais. Int J Rheum Dis 20(10):1572–1581PubMed
Metadata
Title
Performance evaluation of a commercial line blot assay system for detection of myositis- and systemic sclerosis-related autoantibodies
Authors
Yasuhito Hamaguchi
Masataka Kuwana
Kazuhiko Takehara
Publication date
01-11-2020
Publisher
Springer International Publishing
Published in
Clinical Rheumatology / Issue 11/2020
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-020-04973-0

Other articles of this Issue 11/2020

Clinical Rheumatology 11/2020 Go to the issue

Letter to the Editor

COVID-19 reinfection or relapse: an intriguing dilemma

Original Article

Juvenile idiopathic arthritis in Southeast Asia: the Singapore experience over two decades

Original Article

LncRNA CTBP1-AS2 is upregulated in osteoarthritis and increases the methylation of miR-130a gene to inhibit chondrocyte proliferation

Letter to the Editor

Clinical impact of COVID-19 on a French population of spondyloarthritis patients

Original Article

Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis

Editorial

Mitochondrial DNA in osteoarthritis disease
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits